Hair Loss Management

Introduction

• Hair loss can be caused by various conditions, including alopecia areata, a chronic inflammatory condition affecting hair follicles with an autoimmune etiology and T-lymphocyte mediation, according to the British Journal of Dermatology guidelines 1
• Alopecia areata presents as patches of hair loss on the scalp or any hair-bearing skin, and may progress to total scalp hair loss (alopecia totalis) or complete body hair loss (alopecia universalis) 2

Clinical Features and Diagnosis

• Exclamation mark hairs are a characteristic feature of alopecia areata, indicating active disease 1, 2
• A skin biopsy may be necessary in unclear cases or suspected scarring alopecia, as recommended by the British Journal of Dermatology 2
• Diagnostic tools include the pull test, trichoscopy, and hair count to determine the specific cause of hair loss, with the pull test assessing fragility and shedding, trichoscopy examining the scalp and hair follicles, and hair count measuring the number of hairs in a specific area before and after treatment 3, 2
• A comprehensive workup for patients presenting with shedding hair should include a detailed history, physical examination, laboratory testing, and specialized diagnostic procedures to determine the specific cause of hair loss, as recommended by the British Association of Dermatologists 2

Treatment Options

• Intralesional corticosteroid injections (triamcinolone acetonide) are a first-line option for limited patchy hair loss, as recommended by the British Association of Dermatologists and the American Academy of Dermatology, with a 62% success rate 2, 1
• Topical corticosteroids may be considered as an alternative option if intralesional steroids are not tolerated, although evidence for efficacy is limited 1
• Contact immunotherapy with diphenylcyclopropenone (DPCP) has a response rate of 50-60% for extensive patchy hair loss, according to the British Association of Dermatologists, with common side effects including occipital/cervical lymphadenopathy, severe dermatitis, and pigmentary complications in racially pigmented skin 2, 1
• Topical minoxidil 5% has limited efficacy with a response rate of 32-33% for extensive patchy hair loss, as stated by the British Association of Dermatologists 2
• Topical minoxidil 2-5% twice daily is recommended as first-line treatment for female pattern hair loss, with adjunctive treatment including correction of nutritional deficiencies and consideration of antiandrogen therapy if hyperandrogenism is present, as recommended by 4
• Methotrexate (15-25 mg/week) with or without prednisolone is a second-line option, with retrospective data showing 14 of 22 patients with AT/AU achieved complete regrowth 2
• Sulfasalazine is a second-line option, with uncontrolled studies showing partial response but high relapse rate 2
• Cyclosporine is an alternative systemic option, with limited evidence of efficacy in severe disease, and side effects limiting long-term use 2
• Systemic corticosteroids are used as pulse or continuous therapy, with concerns about side effects vs. efficacy ratio, as reported by the British Journal of Dermatology 1
• Prostaglandin F2α analogues (latanoprost, bimatoprost) may have mixed results, with one study showing 45% achieved complete/moderate regrowth after 2 years, and other studies showing minimal response in shorter timeframes 2

Support and Management

• Hair loss can cause significant psychological distress, particularly in young women, and non-pharmacological approaches such as counseling and cosmetic camouflage may be important adjuncts to treatment, as recommended by the British Journal of Dermatology 2
• Consider counseling and referral to patient support groups, as hair loss can cause significant psychological distress, according to the British Journal of Dermatology guidelines 2
• Cosmetic options such as wigs or hairpieces may be considered for extensive hair loss 2
• Follow-up visits to assess response to treatment, repeat photography to document changes, and consideration of quality of life measures are important for managing hair loss effectively, as recommended by the British Journal of Dermatology 2, 1

Special Considerations

• Children with alopecia areata may have limited treatment options, as intralesional corticosteroids are often poorly tolerated, and many clinicians are reluctant to use aggressive treatments like contact immunotherapy in children, as reported by 1
• Misdiagnosing alopecia areata as trichotillomania or tinea capitis can lead to delayed or inappropriate treatment, highlighting the importance of a thorough diagnosis and assessment, as stated by the British Association of Dermatologists 2
• The FDA implemented a "black box" warning for tacrolimus ointment and pimecrolimus cream in 2005 due to potential risk for malignancies, although clinical evidence does not reveal a causal link between increased cancer risk and topical calcineurin inhibitors, as reported by 5